MGC Pharma’s study of the use of cannabinoids to treat aggressive glioblastoma brain cancer has been expanded to explore the effectiveness of its nanoparticle delivery system in improving treatment outcomes.
The delivery system is similar to that being used successfully in the company’s ArtemiC clinical trial into the treatment of COVID-19.
In-vitro results so far show that MGC Pharma-formulated cannabigerol (CBG) can eliminate therapy-resistant glioblastoma stem cells.
The new study, in collaboration with the Slovenian National Institute of Biology and the Neurosurgery Department at the University Medical Centre in Slovenia, will soon begin recruiting new patients with grade IV glioblastomas to be divided into subcategories to receive a personalised treatment plan.
The objective of the pre-clinical in-vitro research is to develop novel formulations to define the clinical protocols for clinical trials for the treatment of high-grade brain tumours with cannabinoids.
MGC Pharma co-founder and managing director Roby Zomer said: “We are now moving forward with our next stage research which will incorporate new and innovative drug-delivery systems.”
“This is a very significant step for our research program and intellectual property, as we look to transform and advance the way brain tumours are treated,” he added.
The ASX-listed company recently made its debut on the London Stock Exchange.